Storia in 2 fonti

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (

Major FDA wins for AstraZeneca: Truqap combination approved for advanced prostate cancer; Ultomiris kidney disease drug gets Priority Review.

Raccontata da

morningstar.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (

Major FDA wins for AstraZeneca: Truqap combination approved for advanced prostate cancer; Ultomiris kidney disease drug gets Priority Review.

originale

morningstar.com1 mese fa

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient…

TRUQAP won FDA approval for PTEN-deficient metastatic prostate cancer with 19% risk reduction—first targeted therapy available. Companion diagnostic approval marks precision medicine maturity: genomic testing bundled with therapy now reshapes oncology development and reimbursement.

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (

Confronto fonti

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient…

Timeline cronologica

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive…

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (